Get the Stockscreener App
1.09
2.83%
0.03
Lexicon Pharmaceuticals Inc stock is traded at $1.09, with a volume of 1.21M.
It is up +2.83% in the last 24 hours and up +0.93% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
See More
Previous Close:
$1.06
Open:
$1.06
24h Volume:
1.21M
Relative Volume:
0.30
Market Cap:
$396.10M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-1.3625
EPS:
-0.8
Net Cash Flow:
$-162.37M
1W Performance:
-5.22%
1M Performance:
+0.93%
6M Performance:
+47.04%
1Y Performance:
-36.99%
1-Day Range:
$1.05
$1.12
1-Week Range:
$1.02
$1.27
52-Week Range:
$0.2836
$2.175
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.09 | 377.93M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.83 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.14 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.69 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
643.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
303.68 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-17-24 | Initiated | H.C. Wainwright | Buy |
| Apr-30-24 | Initiated | Leerink Partners | Outperform |
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
What makes Lexicon Pharmaceuticals Inc. stock price move sharplyFree Technical Signal Summary - newsyoung.net
Is Lexicon Pharmaceuticals Inc. stock entering bullish territoryDay Trading Setup and Momentum Analysis - Newser
Has Lexicon Pharmaceuticals Inc. formed a bullish divergenceShort-Term Market Movement Forecast Report - Newser
Published on: 2025-08-11 05:26:29 - Newser
Real time alert setup for Lexicon Pharmaceuticals Inc. performanceAlpha Stock Picks with Chart Confirmation - Newser
Leerink Partnrs Brokers Increase Earnings Estimates for LXRX - Defense World
Will breakout in Lexicon Pharmaceuticals Inc. lead to full recoveryMarket Timing Strategy with Technical Filters - Newser
Top chart patterns to watch in Lexicon Pharmaceuticals Inc.Free Conservative Long Term Growth Plans - Newser
How high can Lexicon Pharmaceuticals Inc. stock price go in 20252-Day Signal Watch with Forecast Outcome - Newser
Trendline Breach Raises Concern for Lexicon Pharmaceuticals Inc. InvestorsWeekly Return Pick Forecast Reports Show Trend - metal.it
Lexicon Pharmaceuticals Inc. Stock Approaches Key Moving AverageTechnical Stock Breakout Predictions Signal Entry Points - beatles.ru
Lexicon Pharmaceuticals Advances Sotagliflozin Study for Hypertrophic Cardiomyopathy Treatment - AInvest
What momentum shifts mean for Lexicon Pharmaceuticals Inc.Predictive Model for Intraday Swing Forecast - Newser
How sentiment analysis helps forecast Lexicon Pharmaceuticals Inc.Community Picked Stocks with Trade Insights - Newser
Lexicon Pharmaceuticals Advances Study on Sotagliflozin for Hypertrophic Cardiomyopathy - TipRanks
Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Balanced Outlook for Lexicon Pharmaceuticals Amid Strategic Gains and Revenue Challenges - TipRanks
Citigroup Raises Lexicon Pharmaceuticals PT to $1.9, Maintains Buy Rating - AInvest
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Raises Target Price to $1.9 - 富途牛牛
Lexicon: Q2 Earnings Snapshot - New Haven Register
Lexicon Pharmaceuticals 2025 Q2 Earnings Remarkable Turnaround with 106.1% Net Income Increase - AInvest
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.67 Average Target Price from Analysts - Defense World
Lexicon Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Jefferies raises Lexicon Pharmaceuticals stock price target to $0.85 By Investing.com - Investing.com Nigeria
Jefferies raises Lexicon Pharmaceuticals stock price target to $0.85 - Investing.com
Lexicon Pharmaceuticals’ Q2 2025: Navigating Contradictions in Trial Designs, Partnering Strategies, and Financial Guidance - AInvest
Lexicon Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:LXRX) - Seeking Alpha
Lexicon Pharmaceuticals Reports Surprising Q2 Earnings and RevenueNews and Statistics - IndexBox
Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates - sharewise.com
Lexicon Pharmaceuticals Q2 product revenue USD 1.322 million - MarketScreener
LEXICON PHARMACEUTICALS Earnings Results: $LXRX Reports Quarterly Earnings - Quiver Quantitative
Lexicon Pharmaceuticals Inc (LXRX) Reports Q2 2025 Earnings: EPS - GuruFocus
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Lexicon Pharmaceuticals Q2 EPS Surpasses Expectations, Revenue Jumps 1649.7% YoY - AInvest
Lexicon Pharmaceuticals reports Q2 results, Phase 2b PROGRESS study results, and Q3 enrollment target. - AInvest
Evaluating Lexicon Pharmaceuticals' Q2 2025 Earnings and Institutional Investor Sentiment: A Path to Value Creation Amid Mixed Analyst Ratings - AInvest
Published on: 2025-08-04 19:08:28 - metal.it
Lexicon Pharmaceuticals Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) - MSN
Is Lexicon Pharmaceuticals Inc. stock overvalued or undervaluedBuild a winning investment strategy - Jammu Links News
Published on: 2025-08-04 02:57:12 - Jammu Links News
What is the risk reward ratio of investing in Lexicon Pharmaceuticals Inc. stockMarket-beating performance - Jammu Links News
What are Lexicon Pharmaceuticals Inc. company’s key revenue driversUnstoppable profit momentum - Jammu Links News
What are analysts’ price targets for Lexicon Pharmaceuticals Inc. in the next 12 monthsInvest smarter with real-time trading signals - Jammu Links News
What is the dividend policy of Lexicon Pharmaceuticals Inc. stockConsistent triple returns - Jammu Links News
Does Lexicon Pharmaceuticals Inc. stock perform well during market downturnsGet timely alerts on market movers - Jammu Links News
Should I hold or sell Lexicon Pharmaceuticals Inc. stock in 2025Tap into rapid wealth building techniques - Jammu Links News
Is Lexicon Pharmaceuticals Inc. a good long term investmentUnstoppable trading performance - Jammu Links News
How does Lexicon Pharmaceuticals Inc. generate profit in a changing economyMaximize portfolio value with smart investment plans - Jammu Links News
What drives Lexicon Pharmaceuticals Inc. stock priceSky-high profits - Jammu Links News
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):